ACCP 2024 Poster: Lorundrostat Concentration-QTc Results From the First-in-Human Study in Healthy Participants Demonstrate Lack of Relevant Effect and Replaces the Thorough QT Study September 8, 2024
First-in-human study evaluating safety, pharmacokinetics, and pharmacodynamics of lorundrostat, a novel and highly selective aldosterone synthase inhibitor August 26, 2024
AHA Scientific Sessions 2023 Poster: Lorundrostat for Treatment of Obesity-Related, Aldosterone-Dependent Hypertension November 11, 2023
ASN Kidney Week 2023 Poster: Identification of a Hypertensive Endotype with a Median Treatment Effect of -32 mmHg in Response to the Novel Aldosterone Synthase Inhibitor Lorundrostat November 2, 2023
JAMA: Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled Hypertension – The Target-HTN Randomized Clinical Trial September 11, 2023
JAMA Editorial: A New Dawn for Aldosterone as a Therapeutic Target in Hypertension September 10, 2023
AHA Hypertension 2023 Presentation: Target-HTN Trial on the Safety and Efficacy of Lorundrostat (MLS-101) in Patients With Uncontrolled Hypertension September 10, 2023
ACC 2023 Poster: First-In-Human Study of lorundrostat, a Potent and Highly Selective Aldosterone Synthase Inhibitor March 5, 2023
ACC 2023 Poster: Highly Effective Blood Pressure Lowering with lorundrostat, a New Aldosterone Synthase Inhibitor, in Individuals with Obesity and RAAS Dysregulation March 4, 2023
